Anzatax

Anzatax Indications/Uses

paclitaxel

Manufacturer:

Hospira

Distributor:

Zuellig Pharma

Marketer:

Pfizer
Full Prescribing Info
Indications/Uses
Anzatax Injection Concentrate is indicated for the first-line therapy of advanced metastatic ovarian cancer in combination with a platinum agent.
Anzatax Injection Concentrate is indicated for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy.
Anzatax Injection Concentrate is indicated for the first-line therapy in combination with a platinum compound or as a single agent for the treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy.
Anzatax Injection Concentrate is indicated for adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.
Anzatax Injection Concentrate is indicated for the first-line therapy of metastatic cancer of the breast, in combination with trastuzumab (Herceptin), in patients who have tumors that over-express HER-2.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in